Physician profile
Jacob Korula
NPI 1295732568
$3,920.26
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $2,370 · 2021: $218 · 2022: $65.09 · 2023: $110 · 2024: $381 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,681.46 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.03 | 2019-2025 | Xifaxan |
| Abbvie INC. | $252.99 | 2019-2021 | |
| Dova Pharmaceuticals | $200.33 | 2019 | |
| Cvrx, INC. | $169.05 | 2024 | Barostim Neo System |
| Exact Sciences Corporation | $81.39 | 2023-2025 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $69.31 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $42.95 | 2021 | |
| Blueprint Medicines Corporation | $37.56 | 2023 | Ayvakit |
| Eisai INC. | $24.81 | 2019 | |
| Madrigal Pharmaceuticals | $21.86 | 2024 | Resmetirom |
| Intra-Sana Laboratories | $20.63 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| W. L. Gore & Associates, INC. | $18.44 | 2022 | |
| Travere Therapeutics, INC. | $16.43 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $15.02 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Korula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.